Ionis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Ionis with us. And we have Brett Monia, the CEO of the company. So Brett, thanks for being here.
Questions & Answers
And maybe to start here at a high level, could you walk us through your key programs, the outlook for the remainder of 2020 and your strategy here on the [forward]?
Sure. Thank you, Salveen, and it's a pleasure to be here today. So yes, I'd love to give an update on -- at a high level on where the company is today on the key programs.
So starting with SPINRAZA. Of course, SPINRAZA continues to perform as it should, as a blockbuster medicine as it should. We're now approaching nearly 11,000 patients globally that are on SPINRAZA. It is the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |